Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus
Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus
Atea Pharmaceuticals Inc (NASDAQ:AVIR) announced Wednesday new data from the lead-in cohort (n=60) of the company's ongoing Phase 2 combination study of bemnifosbuvir for hepatitis C virus (HCV).
Atea製藥公司（NASDAQ：AVIR）週三宣佈了該公司繼續進行的貝米非韋治療丙型肝炎病毒（HCV）的第二階段聯合研究的引導隊列（n = 60）的新數據。
With an eight-week treatment duration in 60 patients, the Phase 2 data from the lead-in cohort of non-cirrhotic patients showed a 97% sustained virologic response rate at 12 weeks post-treatment (SVR12), the study's primary efficacy endpoint.
在八週的治療期內，60名患者的第二階段引導隊列中，非肝硬化的患者的數據顯示，在治療後12周達到了97％的持續病毒學反應率（SVR12），這是該研究的主要療效終點。
The company will also present preclinical data further demonstrating a high barrier to resistance and pharmacokinetics for bemnifosbuvir and a low risk of drug-drug interactions for ruzasvir.
該公司還將展示預臨床數據，進一步證明貝米非韋具有高抗性和藥代動力學，而魯扎韋的藥物相互作用風險低。
The combination was generally safe and well tolerated. There were no drug-related serious adverse events or treatment discontinuations, and adverse events were mostly mild.
該聯合療法通常安全並且耐受良好。沒有與藥物相關的嚴重不良事件或治療終止，並且不良事件大多是輕度的。
These data will be presented at the European Association for the Study of the Liver (EASL) Congress.
這些數據將在歐洲肝病研究協會（EASL）大會上發佈。
Results from the lead-in cohort of the Phase 2 study also showed a 100% SVR12 rate in participants infected with genotype 3 (n=13), a historically difficult-to-treat genotype of HCV.
第二階段研究的引導隊列的結果還顯示，對於基因型3感染者（n = 13），SVR12率爲100％。這是一種歷史上難以治療的HCV基因型。
The combination regimen was well tolerated, with no drug-related severe adverse events (SAEs) or treatment discontinuations.
該聯合療法方案耐受良好，沒有藥物相關的嚴重不良事件（SAE）或治療中止。
The company says the Phase 2 study continues to enroll up to an additional 220 subjects, including those with compensated cirrhosis.
該公司表示，第二階段研究將繼續招募多達220名受試者，包括那些具有代償性肝硬化的人。
The company said that the results also demonstrated that bemnifosbuvir is at least ten-fold more potent than sofosbuvir, a medication to treat HCV infections, across all genotypes tested and is not resistant to resistance-associated substitutions (RASs) that have been found to alter the activity of sofosbuvir.
公司表示，結果還表明，與治療HCV感染的藥物sofosbuvir相比，貝米非韋的藥效至少要高出十倍，並且不會對已發現改變sofosbuvir活性的抵抗相關替代物（RASs）產生抵抗性。
Following a single oral dose in rats, bemnifosbuvir has favorable overall absorption, distribution, metabolism, and excretion (ADME) properties, including good bioavailability (>60%) and wide distribution to tissues with low penetration into the brain.
大鼠口服單劑量後，貝米非韋的整體吸收，分佈，代謝和排泄（ADME）特性十分有利，包括良好的生物利用度（> 60％）和廣泛的組織分佈，對腦部的滲透性低。
Price Action: AVIR shares are up 2.12% at $3.85 at last check Wednesday.
AVIR股票週三最後一次查詢上漲2.12％，至3.85美元。
Now Read: 152,000 New Jobs Added In May, Missing Expectations: 'Notable Pockets Of Weakness'
現在閱讀：5月新增152,000個就業崗位，低於預期：“顯着的薄弱環節”。
譯文內容由第三人軟體翻譯。